Dopamine agonists for Parkinson's disease

References

Citations

1. Drugs for Parkinson's disease (2004). Treatment Guidelines From the Medical Letter, 2(22): 41–46.

2. Fahn S, Przedborski S (2005). Parkinsonism. In LP Rowland, ed., Merritt's Neurology, 11th ed., pp. 828–846. Philadelphia: Lippincott Williams and Wilkins.

3. Clarke CE, Guttman M (2002). Dopamine agonist monotherapy in Parkinson's disease. Lancet, 360(9347): 1767–1769.

4. Clarke C, Moore AP (2005). Parkinson's disease. Clinical Evidence (14): 1652–1668.

5. Dewey RB, Jr. (2004). Management of motor complications in Parkinson's disease. Neurology, 62 (6, Suppl 4): S3–S7.

6. LeWitt PA (2004). Subcutaneously administered apomorphine: Phamacokinetics and metabolism. Neurology, 62(6, Suppl 4): S8–S11.

7. Bowron A (2004). Practical considerations in the use of apomorphine injectable. Neurology, 62(6, Suppl 4): S32–S36.

Author:	Monica Rhodes	Last Updated: December 13, 2006
Medical Review:	E. Gregory Thompson, MD - Internal Medicine Colin Chalk, MD, CM, FRCPC - Neurology
© 1995-2008 Healthwise, Incorporated. Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.This information does not replace the advice of a doctor. Healthwise disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.